SCHEMBL4714943

SCHEMBL4714943

COC(=O)CC1CCN(C(=O)OC(C)(C)C)Cc2cc(N)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.56
ALDH1A1 P00352 2/20 0.42
ESR2 Q92731 1/20 0.42
NAMPT P43490 2/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MAPK1 P28482 2/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
GPR119 Q8TDV5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4721313 0.88 STS (0.46) NR1H2ALDH1A1ESR2NAMPTUSP30
SCHEMBL4718766 0.88 USP30 (0.42) NR1H2ALDH1A1ESR2NAMPTNPC1
SCHEMBL4718638 0.86 TGFBR1 (0.44) NR1H2ALDH1A1ESR2NAMPTNPC1
SCHEMBL4714474 0.84 GPR119 (0.47) NR1H2ALDH1A1ESR2NAMPTNPC1
SCHEMBL4716513 0.80 TGFBR1 (0.54)
SCHEMBL31730567 0.75 NR1H2 (0.56) NR1H2ALDH1A1ESR2NAMPTMAPK1
SCHEMBL29377835 0.73 NR1H2 (0.90) NR1H2ESR2NAMPTNPC1RAB9A
SCHEMBL29507781 0.73 NR1H2 (1.00) NR1H2ESR2NAMPTNPC1RAB9A
SCHEMBL308035 0.73 NR1H2 (1.00) NR1H2ESR2NAMPTNPC1RAB9A
SCHEMBL61143 0.73 NR1H2 (0.90) NR1H2ESR2NAMPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed